Trial Condition(s):
Diagnostic Imaging
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain further information on tolerability and safety in x-ray Examination (IMAGE)
Bayer Identifier:
14692
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.
Inclusion Criteria
- Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
Exclusion Criteria
- No exclusion criteria besides the contraindications for the use of Ultravist as mentioned in the product information.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Poland | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Indonesia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, South Korea | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Taiwan, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Thailand | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Pakistan | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Romania | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Iran | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Moldova | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Vietnam | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Germany | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Italy | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Hungary | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Russia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Ukraine | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Malaysia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Philippines | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Singapore | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Saudi Arabia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Bosnia and Herzegovina | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Post-marketing surveillance Study Ultravist®-IMAGE IoproMide (UltrAvist®) to Gain further information on tolerability and safety in X-ray Examination
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Occurrence of adverse eventsTimeframe: During and after Ultravist application on the day of examination
Secondary Outcome
- General contrast quality in the region of interest as assessed by physiciansTimeframe: On the day of examination
Additional Information
Copyright © Bayer
Powered by
